Multiple exogenous signals received from cell surface molecules or cytokines play a significant role in altering the host immune response. In chronic autoimmune-mediated diseases, such as multiple sclerosis (MS), immune cells, especially T cells, are involved in the long-term pathophysiology. In the past few decades, mechanisms of pathogenic T-cell involvement at the onset or relapse of disease have been highlighted. However, the factors controlling the disease course have yet to be elucidated because of the complexity of tissue environmental factors. In contrast, dysfunctional or exhausted T cells have been identified as distinct cell lineages in chronic inflammatory diseases, such as cancer or chronic viral infections that show regulatory T cell phenotypes; for example, expressing high levels of co-inhibitory receptors. Regarding cell surface molecule expression, while co-stimulatory molecules promote effector T-cell function, co-inhibitory molecules promote regulatory T-cell function, limiting the inflammatory response. In MS, augmented activation of effector T cells as a result of the impairment of regulatory T-cell function has been implicated. Thus, a comparison between these regulatory T cells in MS and dysfunctional T cells in cancer could provide clues to understand the mechanism of dysregulated T cells, resulting in sustained immune reactions in the long-term disease course of MS. Furthermore, this reveals new immunomodulatory strategies to regain regulatory T-cell function in MS.
Introduction
The clinical course of multiple sclerosis (MS) is highly variable. Although many studies have focused on the factors predisposing the disease onset, little consideration has been given to the factors controlling the disease course after its establishment. Recent studies show that the biology underlying sustained chronic inflammation of immune-mediated disease might be largely distinct from the initial factors predisposing to broken self tolerance. 1 MS is an autoimmune disorder characterized by immune cell infiltration and inflammation within the central nervous system (CNS). Relapsing-remitting MS and secondary progressive MS cause progressive demyelination and neurodegeneration. 2 In the initial relapsing phase of the disease, CD4+ T cells, CD8+ T cells, Bcells and macrophages infiltrate the blood-brain barrier. T cells, particularly CD4+ T helper (Th) cells, such as Th1 and Th17, orchestrate the inflammation involving not only infiltrated peripheral immune cells, but also resident CNS microglia. Subsequent demyelination leads to neurological deficits that are usually recovered after the inflammation has resolved. In the progressive phase of the disease, instead of T cell-mediated inflammation, the accumulation of pre-existing brain injuries and related innate immune system responses in the CNS have been identified as the promoters of neruodegeneration. 3 However, a lymphoid folliclelike structure found in the forebrain meninges of some patients with the progressive phase of MS indicates a contributory role in the underlying subpial gray matter pathology. 4, 5 Throughout the disease course, T cells participate in the pathogenesis of MS. Studying the chronic factors controlling disease course has been disregarded in favor of initiating factors, in part because it requires the prospective collection of long-term follow-up data and the distinctive immune cell lineages representing those disease states are unknown. Dysfunctional or exhausted T cells arising in chronic disease settings; for example, cancer or chronic viral infections, show deficits in effector functions and express high levels of co-inhibitory receptors, such as cytotoxic Tlymphocyte antigen-4 (CTLA4) or programmed death-1 (PD-1), suggesting the potential for a new framework to modify chronic inflammatory disease. 6, 7 The accumulation of inhibitory signals alters T-cell homeostasis to a low functional state. In immunosuppressive environments, such as the tumor microenvironment, T cells receive signals from co-inhibitory receptors concurrently, entering an dysfunctional state as exhausted T cells. Cancer immunotherapy aimed at restoring impaired T-cell function has attracted much attention. 8 However, antibody therapy against co-inhibitory receptors, such as CTLA4 or PD-1, is a double-edged sword, because it also induces the activity of pathogenic T cells in autoimmune diseases, such as myasthenia gravis or MS. 9, 10 Thus, a group of cells expressing co-inhibitory receptors is thought to be key in the tumor microenvironment and the autoimmune disease tissue.
In the present review, potential candidates affecting T-cell states in the chronic disease course of MS are discussed based on emerging evidence of the exogenous factors affecting T-cell function in chronic inflammatory conditions; for example, tumor or chronic viral infection. Furthermore, a strategy for the interpretation of dysregulated T-cell pathophysiology in MS is discussed.
Pathogenic and non-pathogenic T cells in MS
Na€ ıve CD4+ T cells differentiate into several types of Th cells under their antigen stimulation. There are several defined Th cell lineages. In MS, Th1 and Th17 cells that were identified based on the master regulators, T-bet and RORgt, producing either interferon (IFN)c or interleukin (IL)-17, respectively, are thought to be pathogenic. Whereas they are regulated by GATA3-expressing Th2 cells, FoxP3-expressing regulatory T (Treg) cells and IL-10-producing type 1 regulatory (Tr1) cells. 11, 12 Until a couple of decades ago, MS was assumed to be a Th1-mediated disease. However, IFNc treatment of MS patients worsened the disease, providing direct evidence of the pathogenic role of IFNc in MS. 13 As a murine experimental model of MS, experimental autoimmune encephalomyelitis (EAE) models have revealed many aspects of MS etiology. Th1 pathogenicity was also supported by the observation that IL-12p40-deficient (IL-12p40 -/-) mice were resistant to EAE. IL-12 is a heterodimeric proinflammatory cytokine consisting of p40 and p35 chains, which promote Th1 cell differentiation. Interestingly, however, IL-12p35-deficient mice were also susceptible to EAE, raising the question of the involvement of another pro-inflammatory cytokine in EAE pathogenicity. The answer was revealed in 2003, when Cua et al. discovered that IL-23, essential for EAE induction, was part of the IL-12 cytokine family, consisting of p40 and p19.
14 IL-23 was shown as necessary to drive the induction or expansion of CD4+ T cells that secrete IL-17. 15 Therefore, EAE studies to demonstrate a critical role for Th17 cells in the pathophysiology of CNS inflammation accelerated. Today, Th17 cells are defined as a distinct cell lineage, and IL-23 has been identified as unnecessary to the initial differentiation process and instead as a promoter of Th17 development, playing a pathogenic role in CNS inflammation. 12, 16 In contrast, transforming growth factor (TGF)-b1 signaling promotes Foxp3, regulating Treg cell differentiation. In the absence of TGF-b signaling, Th17 cells become highly pathogenic. 17, 18 This suggests that a framework of several factors cooperate to determine the fates of various Th17 cell types from as either pathogenic or non-pathogenic. To this end, two studies analyzing this dynamic regulatory network have shown multiple key transcription factors controlling Th17 cell differentiation. 19, 20 The non-pathogenic Th17 subtype is characterized by regulatory cytokine production, such as IL-9 and IL-10, as well as similar transcription factors found in Tr1 cells, such as c-Maf and AhR, 11 whereas the pathogenic Th17 subtype is denoted by pro-inflammmtory cytokines, such as IFNc, granulocyte-macrophage colony-stimulating factor and IL-22, as well as T-bet expression. It was also shown that EAE brain tissue contains numerous T lymphocytes that co-express IL-17 and IFNc. In line with this, IFNc-producing Th17 cells preferentially cross the in vitro human blood-brain barrier model. 21 This fits the proposed Th17 framework, revealing why IFNc worsens MS.
Regulation of T-cell plasticity in tissues
Although the concept of pathogenic and non-pathogenic Th17 cells sheds light on the initial induction of EAE and MS pathophysiology, when studying the long-term course of a disease, we need to pay attention to exogenous factors affecting T-cell phenotypes, such as input from cell surface molecules or cytokines. Emerging evidence suggests that immature Th cells still have the plasticity to differentiate into Th cells of other phenotypic lineages. 22 Several co-stimulatory and co-inhibitory molecules have been identified on each T-cell type, of which various costimulatory molecules support the pathogenic function of Th1 and Th17, and several co-inhibitory molecules support the regulatory function of Tr1 and Treg cells. 11, 12, 23 Co-stimulatory pathways in MS: CD28, inducible costimulatory molecule (ICOS), CD40, 4-1BB and OX-40 are co-stimulatory molecules in MS During T-cell activation, co-stimulation is often crucial to develop an effective immune response. In cases of autoimmune disease, self antigens, which usually show a low affinity for T-cell receptors (TCR), are affected by a certain amount of co-stimulatory signals that overcome the threshold of T-cell priming, resulting in the differentiation of pathogenic T cells. After T-cell priming, co-stimulatory molecule signals maintain the effector phenotype. Recent studies focusing on co-stimulatory molecules, such as 4-1BB and OX-40, have revealed their involvement in chronic inflammatory conditions, such as tumors or chronic viral infections.
CD28 and ICOS as representative immunoglobulin superfamily members
Most T-cell surface molecules belong to either the immunoglobulin (Ig) superfamily or the tumor necrosis factor receptor superfamily (TNFRSF). 24 Ig superfamily members share a structural domain known as the Ig-like domain, containing not only co-stimulatory molecules, such as CD28 and ICOS, but also co-inhibitory molecules, such as CTLA4, PD-1, T-cell immunoglobulin and mucin domaincontaining protein 3 (Tim-3), Lymphocyte-activation gene 3 (Lag3) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT).
CD28
CD28 is one of the major co-stimulatory molecules expressed on T cells. It is activated by its ligands B7-1 (CD80) and B7-2 (CD86), and coordinates with signaling, promoting T-cell proliferation and survival during T-cell priming. CD28 is essential for the development of EAE in C57BL/6J mice and other autoimmune disease models. 25, 26 Using SJL/J mice exhibiting a relapse-remitting form of EAE, it was shown that blocking with anti-B7-1 reduced Th1 differentiation and epitope spreading, instead promoting Th2 cell differentiation and amelioration of the EAE model. 27, 28 Notably, CD86 was generally observed in inflammatory brain lesions, such as active stroke lesions or MS plaques, whereas CD80 was only expressed in MS plaques, which might indicate a specific pathogenic role of CD80 in MS. 29 
ICOS
ICOS is expressed on activated T cells, thereby inducing optimal activation of T cells, as in TCR stimulation. Although constitutive expression of ICOS on T cells is not as rapid as CD28, 30 it is expressed on Th2, Th17 and follicular Th cells, and binds with B7RP-1 (inducible co-stimulator ligand), which is expressed on B cells and macrophages. 31, 32 Th17 cells are pathogenic for EAE induction. Conventional Th17 cells do not require ICOS co-stimulation for their initial differentiation. However, ICOS is necessary for IL-23-driven population expansion of already differentiated Th17 cells to become pathogenic. In line with this, it has been reported that ICOS induces robust expansion of human IL-17 + IFNc + T-cell differentiation. 33 Interestingly, ICOSdeficient mice develop more severe EAE with enhanced Th1 and Th17 cell cytokine production, possibly because of the reduction of IL-4 and IL-10 production from Th2, and other regulatory T cells limit Th1 and Th17 cell priming. 34, 35 This suggests a differential role of ICOS for T-cell priming, expansion and survival during the disease.
CD40, 4-1BB and OX-40 as representative TNFRSF members
The TNFRSF is a family of 29 structurally similar receptors expressed on T cells that play a key role in regulating the development and homeostasis of the immune system, as well as the CNS, in mammals. 36 Many of these receptors have been investigated for their role in pathogenic T-cell activation and survival in EAE. For example, CD40 (TNFRSF5) and its ligand (CD40L) are expressed on T cells that interact with antigen presenting cells (APC), and aid in cytotoxic CD8 T-cell priming and activation. 37, 38 The CD40-CD40L axis also stimulates APC to upregulate B7-for CD28-mediated co-stimulation, producing proinflammatory cytokines, such as IL-12, activating platelets, and triggering the inflammatory reactions of endothelial cells. [39] [40] [41] Thus, CD40L-deficient mice do not develop EAE. 42 4-1BB (TNFRSF9) enhances CD28 co-stimulation, promoting Th1 differentiation. 43 Thus, a deficiency of 4-1BB ligand results in resistance to EAE induction, reduction in Th1 and Th17 cell cytokine production, and autoreactive T-cell infiltration. 44 It has been reported that 4-1BB co-stimulatory signals can cooperate with immune checkpoint inhibitors, such as blocking programmed death ligand 1 (PD-L1) and augmenting cytotoxic CD8 T-cell response in chronic viral infections. 45 Thus 4-1BB might also play a role in maintaining differentiated T cells in the tissue.
OX-40 (TNFRSF4) is a T-cell co-stimulator resulting in enhanced cell proliferation, survival, effector function and migration. 46 In EAE, OX40 is unnecessary for the initial disease induction, as a deficiency did not result in complete protection against EAE. However, OX40 mediates autoreactive T-cell priming, migration and function, indicating a role in latestage EAE. [47] [48] [49] In line with this, OX-40 agonistic therapy has proven a potent cancer immunotherapy, enhancing CD8 tumor infiltration. 50 Co-inhibitory pathways in MS: CTLA4, PD-1, Tim-3, Lag3 and TIGIT are co-inhibitory molecules in MS When priming T cells receive co-inhibitory signals, they do not become fully activated and rather differentiate into regulatory T cells. While overactivation of co-stimulatory signals leads to MS pathogenesis, insufficient co-inhibitory signals promote the development and progression of MS. A CTLA4 and PD-1 deficiency results in the development of spontaneous autoimmunity, and antagonistic CTLA4 and PD-1 antibodies are clinically available for treating cancer patients. [51] [52] [53] Also, recent studies have shown that multiple co-inhibitory molecules, such as Tim-3, Lag3 and TIGIT, appear to play an important role in regulating autoimmunity and cancer immunity. 
CTLA4
CTLA4 is a co-inhibitory receptor that competes with CD28, playing a pivotal role in the regulation of Tcell activation and promoting self-tolerance in the peripheral immune system. CTLA4 dysregulation was identified in myelin basic protein-reactive T cells from MS patients compared with healthy controls. Blocking antibody treatment against CTLA4 on myelin basic protein-reactive T cells promoted proliferation and cytokine production in healthy controls, but less in those T cells from MS patients. 54 In mice, germline CTLA4 deficiency resulted in a lymphoproliferative disorder and death within 4 weeks of birth, whereas conditional deletion of CTLA4 on Foxp3-expressing Treg cells in adult mice resulted in exacerbated EAE. 55 This highlights the differential role of CTLA4 in the thymus versus the peripheral immune system. Notably, it was reported that a melanoma patient treated with anti-CTLA4 antibodies developed MS. 10 
PD-1
PD-1 is a co-inhibitory molecule regulating MS and EAE. Polymorphisms in the PD-1 gene (PDCD1) locus appear to be associated with disease progression in MS patients. 56 PD-1 and its ligands, PD-L1
and PD-L2, are expressed on CNS-infiltrating cells, but not on the endothelium or microglia in EAE mice. 57, 58 In line with this, PD-1-and PD-L1-deficient mice were more susceptible to induced EAE than a wild-type control or PD-L2-deficient mice. 59 Interestingly, the PD-L1 expression on circulating dendritic cells was lower in patients with secondary progressive MS than in healthy individuals or relapsing-remitting MS patients. PD-L1-dendritic cells showed an increased percentage of pro-inflammatory cytokine IL-12 production, which might indicate a constitutive lack of immune regulation in the chronic progressive phase of MS. 60 Of note, IFN-b treatment induces PD-L1 mRNA expression in MS, which might explain a part of the anti-inflammatory effect of IFN-b. 61 
Tim-3
Tim-3 expression was initially reported on Th1 cells, and Tim-3 antibody treatment exacerbated EAE induction. 62 In line with its expression on Th1 T cells, Tim-3 deficiency regulates Th1-, but not Th17-, cell-driven adoptive transfer of EAE. 63 Indeed, low expression of Tim-3 was observed in the peripheral blood and cerebrospinal fluid of MS patients. 64 Importantly, Tim-3 expression is regained in MS after glatiramer acetate or IFN-b treatment, stabilizing the disease and reducing relapses.
Lag3
Lag3 is a CD4-associated adhesion molecule that binds to major histocompatibility complex class II molecules and inhibits activated T cells. Lag3 polymorphism is reportedly associated with MS. 66 Although Lag3 deficiency alone does not enhance autoimmune disease models, 7 it was reported that Lag3 was highly expressed on gut T cells from myelin antigen-reactive TCR transgenic mice (2D2 mice), and that Lag3 plays a suppressive role for ameliorating EAE by adoptive transfer. 67 In line with this, high-dose auto-antigens drive the generation of regulatory T cells that express Lag3 together with PD-1, Tim-3 and TIGIT, and produce the immunosuppressive cytokine, IL-10. 68 
TIGIT
Recently, TIGIT was implicated as an inhibitory molecule modulating the course of MS. Transgenic mice overexpressing TIGIT or mice treated by a TIGIT agonistic antibody showed reduced EAE induction, whereas TIGIT-deficient mice were more susceptible to EAE. 69 TIGIT binds two ligands, CD155 and CD112, which are expressed on APC, T cells and a variety of non-hematopoietic cell types, including tumor cells. CD226 provides a co-stimulatory signal to T cells by binding to these ligands. Therefore TIGIT, CD226 and their ligands play a role reminiscent of CTLA4, CD28 and B7 ligands. Interestingly, genome-wide association studies have linked a single-nucleotide polymorphism in CD226 (Gly307Ser) to multiple autoimmune diseases including MS. 70 
Regulatory cytokines in T-cell maintenance
In the process of long-term maintenance of T cells in the tissue, some of the immune regulatory cytokines have also been described as playing important roles on T cells.
TGF-b
TGF-b was originally described as a factor transforming non-malignant cells into neoplastic cells. Today, it is recognized as being produced from immune cells as well as tissue cells, including the CNS. There are three isoforms: TGF-b1, TGF-b2 and TGF-b3, In particular, TGF-b1 involvement limits the systemic immune response in TGF-b1-deficient mice showing spontaneous systemic inflammation. 71 Although analysis of peripheral blood TGF-b in MS patients is controversial, it was reported that a high number of MS relapses correlates with a high level of biologically active TGF-b1 in cerebrospinal fluid. 72 It was also reported that CNS-infiltrating macrophages and hypertrophic astrocytes expressed TGF-b isoforms and their receptors in active demyelinating MS lesions, as well as in chronic and inactive MS lesions. 73 Interestingly, lethal inflammation in TGFb1-deficient mice was inhibited by further depleting CD4+ T cells, suggesting the critical role of TGF-b1 in regulating pathogenic CD4+ T cell differentiation. 74 Thus, TGF-b1 has been studied extensively in the immune system, especially on CD4+ Th cells. It is well documented that TGF-b influences the differentiation of na€ ıve CD4+ T cells into effector T cells of different phenotypes. Most notably, TGF-b promotes the differentiation of Foxp3-expressing Treg cells. 75 The combination of TGF-b + IL-6 was shown to drive Th17 cell differentiation in vitro, 16 and TGFb + IL-4 was shown to drive IL-9-and IL-10-producing Th9 cell differentiation in vitro. 76 As TGF-b drives non-pathogenic Th17 cells, these results show that TGF-b signals regulate multiple lineages of Th cells. Furthermore, it was reported that TGF-b is important for regulating CD8+ T-cell activation and proliferation, and that TGF-b depletion contributes to ameliorating inflammation in TGF-b1-deficient mice. 77 Although considerably less is known about how TGF-b affects effector T cells at inflammation sites, Huss et al. reported that TGF-b1 promotes initial myelin-specific Th1 cell differentiation. However, TGFb1 exposure through multiple rounds of antigen activation results in the accumulation of IL-10-producing cells and a reduction in the ability to induce EAE. 78 More recently, it was reported that TGF-b and aryl hydrocarbon receptor signals on CNS-infiltrating Th17 cells promote their further differentiation toward IL-10-producing Tr1 cells in the tissue. 79 TGF-b1 was reported to mediate Smad3, which enhances PD-1 expression on tumor antigen-specific T cells, and might play multiple roles in regulating the effector function of T cells. 80 
IL-27
IL-27, a heterodimeric cytokine and a member of the IL-12 cytokine family, consists of p28 and Ebi3, which are produced by APC or resident tissue cells. In the MS brain, IL-27 and IL-27 receptor expression was elevated compared with the healthy control brain. CNS-infiltrating T cells expressed high levels of IL-27 receptors in the MS brain, whereas astrocytes, microglia and macrophages were the main source of IL-27. 81 Although IL-27 was initially shown to promote pro-inflammatory type 1 immune responses, emerging evidence suggests that this cytokine is important in the resolution of tissue inflammation. 82 IL-27 administration in vivo suppresses the pathogenicity of primed effector T cells and inhibits the development of EAE. 83 In line with a suppressive function for IL-27, IL27ra-deficient mice showed increased inflammation during Toxoplasma gondii infection. 84 Indeed, it has been shown that IL-27 stimulation during Th cell differentiation induces IL-10-secreting Tr1 cells that are immune suppressive Figure 1 T cell activation and plasticity in multiple sclerosis (MS). In conventional T-cell activation in chronic inflammatory diseases, such as cancer or chronic viral infection, na€ ıve T-cells recognize the antigen presented by antigen presenting cells due to the co-stimulation of CD28, CD40 and 4-1BB. When priming T cells express cytotoxic T lymphocyte antigen-4 (CTLA4) or programmed death ligand 1 (PD-L1), they do not become fully activated and rather differentiate into regulatory T cells (priming phase). After priming, differentiated effector T cells, further expanded by the co-stimulation of CD28 or inducible co-stimulatory molecule (ICOS), are involved in tissue inflammation (expansion phase). In the tissue, multiple factors provide regulatory signals to the effector T cells, producing either dysfunctional effector cells or regulatory cells, unless they undergo activation-induced cell death or memory cells death resulting in the resolution of tissue inflammation (maintenance phase). In MS, initial factors including co-stimulatory molecules predisposing to broken self-tolerance induce predominant pathogenic T-cell priming. After priming, differentiated pathogenic T cells; for example, T helper 1 and T helper 17 cells, further expand and become involved in central nervous system inflammation. In the central nervous system, dysregulation through insufficient co-inhibitory signals induces sustained inflammation involved in demyelination and neurodegeneration throughout the long-term course of MS. IFNc, interferon-c; IL, interleukin; PD-1, programmed death-1; TGF-b, transforming growth factor-b; TIGIT, T-cell immunoreceptor with immunoglobulin and ITIM domains; Tim-3; T-cell immunoglobulin and mucin domain-containing protein 3. Lag3; Lymphocyte-activation gene 3. and ameliorate EAE. 11, 83 In line with this, the role of IL-27 inducing co-inhibitory molecules has been emphasized. For example, IL-27 stimulation under Th17 cell differentiation promotes T cells to express PD-L1, resulting in the inhibition of Th17 differentiation and suppressing EAE induction. 85 Furthermore, IL-27 stimulation enhances Tim-3 expression on Th1 cells, skewing them toward IL-10-producing cells. 86 These results pose an interesting question as to whether IL-27-driven gene signatures might be a useful tool to identify a gene module regulating effector T cells toward a less immune reactive phenotype by expressing multiple co-inhibitory molecules and regulatory cytokines, such as IL-10. 87 
Conclusion
Multiple co-stimulatory and co-inhibitory molecules, as well as cytokines, are involved in maintaining T cells in chronic inflammatory diseases. While CD28, CD40 or 4-1BB play a critical role in the T-cell priming phase, ICOS is important for the expansion of effector T cells. 4-1BB and OX40 maintain effector T cells, resulting in their long-term survival. CTLA4 antagonizes the initial T-cell priming phase induced by CD28. PD-L1 on T cells can skew the initial differentiation of effector Th17 cells. In contrast, PD-1, Tim-3, Lag3 and TIGIT limit the effector capacity of activated T cells, preventing activation-induced cell death and differentiating them to dysfunctional or immune regulatory cells, such as Tr1 cells. Immune regulatory cytokines; for example, TGF-b and IL-27, regulate T-cell differentiation, and function directly or indirectly through the induction of co-inhibitory molecules (Fig. 1) . In MS, many of the co-inhibitory molecules are dysregulated, showing lower expression on T cells, resulting in excessive co-stimulatory molecule signals and sustained chronic inflammatory responses in the tissue. A high TGF-b level in the cerebrospinal fluid of MS, as well as elevated expression of IL-27R on T cells in the MS brain, can be explained as a compensatory mechanism for this dysregulation.
In the chronic inflammatory tissue environment, such as the tumor microenvironment, repeated stimulation of antigens, immune regulatory metabolic states, and signals from cell surface molecules and cytokines facilitate T-cell differentiation to the dysfunctional state. Because of the clinical success of antibody treatment targeting CTLA4 or PD-1, we are confident at these co-inhibitory molecules play a pivotal role in limiting effector T-cell functions in at least some cancer patients. However, there are a number of other co-stimulatory and co-inhibitory molecules affecting T-cell function, but it is still unknown how predominantly they are distributed on the surface of dysfunctional T cells. Furthermore, it is also unclear whether they collaborate or antagonize with other cell surface molecules as cis: interact within the same cell or trans: interact between multiple cells. To answer these questions, we need a global analysis of co-stimulatory and co-inhibitory molecules on dysfunctional T cells, and to determine the key transcription factors connecting them.
As a mirror image in the resolution and chronic inflammatory phase of MS, it remains unclear whether effector T cells, after infiltrating the tissue, are signaled to become regulatory T cells from cis expressed co-inhibitory and co-stimulatory molecules or die through trans suppression by co-infiltrating regulatory T cells. Furthermore, it also needs to be determined how these signals on infiltrated T cells in the MS brain are dysregulated, resulting in sustained chronic inflammation. Understanding the dysregulated T cells in MS requires the prospective collection of long-term follow-up data to elucidate the distinctive immune cell lineages representing chronic inflammation in autoimmune disease. Although this is challenging, it provides a new therapeutic strategy promoting immune modulation toward preferable T-cell states regulating inflammation. Emerging studies of T cells in highly immunesuppressive environments, such as the tumor microenvironment, might provide clues to ascertain such immune cell lineages in autoimmune disease.
